Device Trial Radar · NCT00996489
This is a Post Approval Study of Coaptite® in the Treatment of Female Urinary Incontinence
Last checked: Nov 20, 2026Latest source record: Jul 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
459
Actual
Start
Jan 8, 2008
Primary completion
Oct 26, 2015
Study completion Nov 2, 2015
Sponsor
- Lead sponsor
- Merz North America, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 16, 2009
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a post approval study of Coaptite® in the treatment of female urinary incontinence.
Conditions
- Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency
Interventions
Coaptite®Device
Calcium hydroxylapatite particles suspended in an aqueous based gel carrier
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incontinence Status as Assessed by Stamey Grade ScoreTime frame: Baseline and Months 6, 12, 18, 24, 30, and 36
- Number of Participants With One Point Improvement in Stamey Grade Scores up to Month 12Time frame: Baseline up to Month 12
- Number of Participants Who Had at Least One Point Improvement in Stamey Grade Scores Compared to BaselineTime frame: Months 6, 12, 18, 24, 30, and 36
2 more outcomes with a free account
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Wetumpka, Alabama
Site not named
Surprise, Arizona
Site not named
Encinitas, California
17 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.